- Previous Close
55.82 - Open
54.94 - Bid 55.39 x 400
- Ask 55.53 x 300
- Day's Range
54.60 - 55.62 - 52 Week Range
45.22 - 60.12 - Volume
1,558,714 - Avg. Volume
2,590,121 - Market Cap (intraday)
135.77B - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
23.21 - EPS (TTM)
2.39 - Earnings Date Apr 24, 2025
- Forward Dividend & Yield 2.04 (3.67%)
- Ex-Dividend Date May 9, 2024
- 1y Target Est
63.72
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, yellow fever, and rabies vaccines. In addition, the company has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Innate Pharma SA for a natural killer cell engager program targeting B7-H3; and Blackstone Life Sciences to develop pivotal studies and clinical development program. Further, it has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop novel targeted protein degradation therapies; Denali Therapeutics Inc. to treat a range of systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for the discovery and development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
www.sanofi.com82,878
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SNY
View More
Performance Overview: SNY
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNY
View MoreValuation Measures
Market Cap
136.70B
Enterprise Value
147.47B
Trailing P/E
23.68
Forward P/E
12.50
PEG Ratio (5yr expected)
1.15
Price/Sales (ttm)
2.95
Price/Book (mrq)
1.64
Enterprise Value/Revenue
3.08
Enterprise Value/EBITDA
12.38
Financial Highlights
Profitability and Income Statement
Profit Margin
12.56%
Return on Assets (ttm)
4.28%
Return on Equity (ttm)
7.30%
Revenue (ttm)
44.29B
Net Income Avi to Common (ttm)
5.5B
Diluted EPS (ttm)
2.39
Balance Sheet and Cash Flow
Total Cash (mrq)
7.56B
Total Debt/Equity (mrq)
23.01%
Levered Free Cash Flow (ttm)
-4.94B
Research Analysis: SNY
View MoreResearch Reports: SNY
View MoreLed by Dupixent, Solid Immunology Position Helps Support Steady Long-Term Growth for Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
RatingPrice TargetHealthcare Policy: RFK Jr. Confirmed to Lead HHS, but Biopharma Uncertainty Captured in Our Ratings
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
RatingPrice TargetHealthcare Policy: RFK Jr. Confirmed to Lead HHS, but Biopharma Uncertainty Captured in Our Ratings
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
RatingPrice TargetThe Argus High-Yield Model Portfolio
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022 and have taken an early lead in 2025. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But the rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.